One Step Closer to a Breath Test for Lung Cancer
May 31, 2014 · Comments Off on One Step Closer to a Breath Test for Lung Cancer
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
December 2, 2013 · Comments Off on Fingerprint Cancer
Where a Cancer Lives May not be as Important as What it’s Made of Imagine...
IASLC Names Fred R. Hirsch, MD, PhD as New CEO
November 6, 2013 · Comments Off on IASLC Names Fred R. Hirsch, MD, PhD as New CEO
The International Association for the Study of Lung Cancer (IASLC) Board of Directors has selected Fred R. Hirsch, MD, PhD as the organization’s new Chief Executive Officer (CEO). Hirsch takes over for the current CEO, Paul A. Bunn, Jr., MD.
Study: Redefining the criteria for ALK positive lung cancer
September 10, 2013 · Comments Off on Study: Redefining the criteria for ALK positive lung cancer
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.
New marker of drug response may speed pace of lung cancer prevention trials
January 8, 2013 · Comments Off on New marker of drug response may speed pace of lung cancer prevention trials
Testing medicines to prevent lung cancer requires treating many thousands of high-risk individuals and then waiting 5, 10 or 15 years for results. A possible waypoint on the way to benefit may dramatically speed testing.
Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
August 29, 2012 · Comments Off on Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark...
Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
August 28, 2012 · Comments Off on Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Prestigious SPECS grant promises targeted treatments for squamous cell lung cancer
March 6, 2012 · Comments Off on Prestigious SPECS grant promises targeted treatments for squamous cell lung cancer
THREE KEY POINTS: Fred R. Hirsch will coordinate multimillion dollar, multi site SPECS grant from...
New device uses gold nanoparticles to test for lung cancer
November 16, 2011 · Comments Off on New device uses gold nanoparticles to test for lung cancer
The metabolism of lung cancer patients is different than the metabolism of healthy people. And...
Dietary supplements shown to increase cancer risk
November 16, 2011
Bitter melon juice prevents pancreatic cancer in mouse models
November 16, 2011
Promising Breast and Ovarian Cancer Treatment Vaccine Comes to UCH
November 16, 2011
AACR amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer grants cancer prevention cancer research colorado Cancer Survivorship clinical trial colon cancer colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
The Internet is down. There are no treats in the copy room. The sky is falling! The sky is falling!